NWM
TBPH icon

Nova Wealth Management’s Theravance Biopharma TBPH Stock Holding History

Nova Wealth Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$714 Hold
42
– – ﹤0.01% 553
2026
Q1 		$682 Hold
42
– – ﹤0.01% 525
2025
Q4 		$786 Hold
42
– – ﹤0.01% 560
2025
Q3 		$613 Hold
42
– – ﹤0.01% 566
2025
Q2 		$463 Hold
42
– – ﹤0.01% 717
2025
Q1 		$375 Hold
42
– – ﹤0.01% 525
2024
Q4 		$395 Buy
+42
New +$382 ﹤0.01% 358

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Nova Wealth Management's TBPH Position: Q2 2026 in Review

Nova Wealth Management held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 42 shares worth $714. The position accounts for ﹤0.01% of the portfolio, ranked #553.

Nova Wealth Management first reported a position in TBPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $786 in Q4 2025. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Nova Wealth Management held 42 shares of Theravance Biopharma worth $714 as of Q2 2026.
  • Nova Wealth Management left its Theravance Biopharma share count unchanged in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Nova Wealth Management's portfolio in Q2 2026, its #553 holding.
  • Nova Wealth Management first reported a position in Theravance Biopharma in Q4 2024 and has held it in 7 quarters since.
  • Nova Wealth Management's Theravance Biopharma position peaked at $786 in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Nova Wealth Management's 13F filing for Q2 2026, filed 13 Jul 2026.